Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Blueprint Medicines at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Blueprint Medicines brings 1 presentation to ASH 2026 in New Orleans. Its program centres on systemic mastocytosis. It presents a session on indolent mastocytosis and supports two symposia on diagnosing and treating the disease across its stages.

OrganizationASH 2026 Attendance
Blueprint Medicines
Cambridge, MA
Biotech
Precision therapy company, now part of Sanofi, known for avapritinib for systemic mastocytosis.
Symposium
Fri Dec 11
11:00am–2:00pm
Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease
Diagnosing systemic mastocytosis, separating indolent from advanced disease, preventing anaphylaxis, and choosing between symptom control and Kit-targeted drugs.
Symposium hosted by Decera Clinical Education
Leukemias
Symposium
Fri Dec 11
7:00pm–10:00pm
Clinical Turning Points: Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis
Recognizing the full symptom burden of non-advanced systemic mastocytosis, judging disease control, and deciding when to escalate to disease-directed therapy.
Leukemias

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Blueprint Medicines

Tell us what you sell and we’ll find the people at Blueprint Medicines most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction